CClinicalTrials.gg
Status unknownNCT04598971PHURINEUpdated Oct 22, 2020

Urine pH and Urinary Tract Infection

An observational study in Urinary Tract Infections and Urinary Stone, sponsored by Centre Hospitalier Universitaire Vaudois. Status unknown at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-22.

Sponsored by Centre Hospitalier Universitaire Vaudois · Observational

The sponsor has not verified this record recently (last verified Oct 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Urinary tract infections (UTI) affect the urine pH and may lead to salt precipitation such as struvite. Bacteria with urease activity are known to alkalinise urine, but not much is known on how pH is changing over time during UTI.

This study aims at following urine pH progression at the time of diagnosis of UTI and during the treatment phase.

Description of the change in urine pH over time will help understanding the risk of struvite formation and potential timing of intervention.

Read the detailed description

Adults presenting with UTI symptoms will be screened for infection and instructed to monitor urine pH during the course of treatment and 1 week after. Urine pH will be measured by the patients using calibrated pH-stix. Type of bacteria, antibiotics, and the type of diet will be monitored during the study.

02

Conditions studied

  • Urinary Tract Infections
  • Urinary Stone

Keywords

  • urine pH
03

In context

Infections

6,688 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's planned enrollment of 50 is below the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Centre Hospitalier Universitaire Vaudois is the lead sponsor of 203 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patient consulting the primary care unit of the medical outpatient clinic UniSanté in Lausanne will be asked to participate.

Eligibility criteria

Group 1. Cystitis

Inclusion Criteria:

  • Symptoms of dysuria, pollakiuria, no fever AND
  • urine-stix positive for leucocytes OR positive culture (>10E5 cfu/ml)

Group 2. Pyelonephritis

Inclusion Criteria:

  • Unilateral flank pain, pollakiuria, dysuria, fever (>38.5°C) AND
  • urine-stix positive for leucocytes OR positive culture (>10E5 cfu/ml)

Exclusion Criteria (both groups):

  • known urinary tract anatomic abnormalities
  • Presence of a urine catheter
  • Sepsis - septic shock
  • Patient taking drug interfering with urine pH (diuretics, citrate, acetazolamide, topiramate,...)
  • Patients with UTI diagnosed in the preceding month
  • Patients having received antibiotics during the preceding month
  • Male patient with a diagnosis of prostatitis
  • Presence of infected kidney cyst
  • Patient with diabetes
  • Pregnant female
  • Patient with obstructive pyelonephritis
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cystitis

    Patients with lower UTI will be included in this group

  • Pyelonephritis

    Patients with higher UTI will be included in this group

06

What researchers measure

Primary outcomes

  1. Urine pH

    Urine pH is monitored by the patient every morning during the treatment phase and 7 days after the end of treatment

    Time frame: 21 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04598971
Lead sponsor
Centre Hospitalier Universitaire Vaudois
Responsible party
Olivier Bonny (Associate professor, Centre Hospitalier Universitaire Vaudois) — Principal investigator
First posted
Oct 22, 2020
Start date
Aug 1, 2020
Primary completion
Dec 31, 2020 (estimated)
Completion
Dec 13, 2021 (estimated)
Last update
Oct 22, 2020

Study contacts

Charlotte Desponds, BM
Contact
Charlotte.Desponds@unil.ch
+41795561934
Alexandre Gouveia, MD
Contact
Alexandre.Gouveia@unisante.ch
Olivier Bonny, MD-PhD
principal investigator · CHUV-Lausanne

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion